I-Mab has released a corporate presentation highlighting its advancements in cancer therapeutics, particularly focusing on givastomig, a novel bispecific antibody targeting CLDN18.2, which is being developed for gastric cancer treatment. The presentation outlines clinical data showcasing anti-tumor activity with limited toxicities and higher binding affinity across various CLDN18.2 expression levels. Gastric cancer, a global market valued at $12 billion, presents a significant opportunity for expansion into other tumor types. The company is progressing with a Phase 1b escalation study of givastomig in combination with nivolumab and chemotherapy, with topline data to be presented at the upcoming ESMO GI 2025. Additionally, I-Mab maintains a strong capital position with $168.6 million in cash, ensuring financial stability through major clinical readouts. You can access the full presentation through the link below.